Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia

Affiliations

¹ Hematology/Oncology Fellowship Program, University of Washington, Seattle, WA;
² Public Health Sciences Division and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA;
³ Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Pediatrics, and Department of Microbiology and Immunology, Weill Cornell Medical Center, New York, NY;
⁴ Department of Infectious Diseases, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, TX; and.
⁵ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medicine, Division of Hematology, and Department of Epidemiology, University of Washington, Seattle, WA.

Review

Anna B Halpern et al. Blood. 2015.

. 2015 Dec 24;126(26):2790-7.

doi: 10.1182/blood-2015-07-627323. Epub 2015 Oct 26.

¹ Hematology/Oncology Fellowship Program, University of Washington, Seattle, WA;
² Public Health Sciences Division and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA;
³ Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Pediatrics, and Department of Microbiology and Immunology, Weill Cornell Medical Center, New York, NY;
⁴ Department of Infectious Diseases, Division of Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, TX; and.
⁵ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Medicine, Division of Hematology, and Department of Epidemiology, University of Washington, Seattle, WA.

No abstract available

Figures

1. Pechlivanoglou P, Le HH, Daenen S, Snowden JA, Postma MJ. Mixed treatment comparison of prophylaxis against invasive fungal infections in neutropenic patients receiving therapy for haematological malignancies: a systematic review. J Antimicrob Chemother. 2014;69(1):1–11. - PubMed
1. Leventakos K, Lewis RE, Kontoyiannis DP. Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis. 2010;50(3):405–415. - PubMed
1. Tacke D, Buchheidt D, Karthaus M, et al. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Ann Hematol. 2014;93(9):1449–1456. - PubMed
1. Neofytos D, Horn D, Anaissie E, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48(3):265–273. - PubMed
1. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091–1100. - PubMed